Is fixed-dose combination therapy (polypill) that combines antiplatelet, blood pressure–lowering, and cholesterol-lowering medications into a single pill associated with improved cardiovascular disease (CVD) risk factors or reduced all-cause mortality or fatal and nonfatal CVD events? Is the polypill associated with an increase in adverse events?
Polypills are associated with greater reductions in systolic blood pressure and total cholesterol compared with usual care, placebo, or active comparators, but also with a 19% higher risk of any adverse event. Due to limited power from available evidence, the association of polypills with all-cause mortality or fatal and nonfatal CVD events is uncertain.
Huffman MD, de Cates AN, Ebrahim S. Fixed-Dose Combination Therapy (Polypill) for the Prevention of Cardiovascular Disease. JAMA. 2014;312(19):2030–2031. doi:10.1001/jama.2014.13616
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.